RIGL FY 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$179M+53.4% YoY

Gross Profit

$161M89.6% margin

Operating Income

$24M13.5% margin

Net Income

$17M9.8% margin

EPS (Diluted)

$0.99

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$31M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$164M

Total Liabilities

$161M

Stockholders' Equity

$3M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$179M	$117M	+53.4%
Gross Profit	$161M	$110M	+46.3%
Operating Income	$24M	-$20M	+218.1%
Net Income	$17M	-$25M	+169.7%